0

Ademar Dantas da Cunha Junior

UNIOEST University, Brazil

Title: Metformin is a reposing and potential drug to prevent Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma

Abstract

Epidemiological and preclinical research studies indicate that metformin is a potential therapeutic target in patients with leukemia, lymphomas, and multiple myeloma. Metformin might conduct to systemically reduce the levels of proinflammatory soluble mediators (e.g., IL-6 and IGF-1), which is mediated via AMPK, mTOR, as well as displaying an isolated and synergistic effect with common antimyeloma drugs. Besides that, diminish activation of the MEK/MAPK, JAK/STAT, and PI3K/AKT signaling pathways might be involved with effect of metformin in microenvironment and neoplastic cells. It is expected that the diverse pleiotropic effects of the drug act on multiple targets, specifically in myeloma, in which there is a strong interaction between the clonal plasma cells and the BM microenvironment which should be explored earlier in Natural History and Spectrum of Disease.

Biography

Clinical Hematologist/oncologist and researcher at UNIOESTE and Cancer Hospital in Cascavel, Parana state, Brazil. Professor at internal Medicine at UNIOSTE. In addition to her teaching undergraduate, graduate, and extension activities, she works in clinical and translational research with an interest in the study of changes in body composition, inflammation, molecular and new therapeutic strategies in myeloid and plasmatic neoplasms. In the last year have been published five papers related to his fields.